XM không cung cấp dịch vụ cho cư dân của Mỹ.
L
L

LaboratoryCorporation


Tin tức

U.S. STOCKS Newmont, Monopar Therapeutics, TKO Group

BUZZ-U.S. STOCKS ON THE MOVE-Newmont, Monopar Therapeutics, TKO Group Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq jumped on Thursday, driven by Tesla's positive earnings forecast, which buoyed market sentiment despite declines from other corporate results and pressure from rising Treasury yields.
A
B
D
H
N
T
T
L
A
L
T
T
U
U
D
S
T
C
L
R
T

Labcorp Holdings Inc reports results for the quarter ended in September 30 - Earnings Summary

Labcorp Holdings Inc reports results for the quarter ended in September 30 - Earnings Summary Labcorp Holdings Inc LH.N reported quarterly adjusted earnings of $3.50​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $3.38. The mean expectation of seventeen analysts for the quarter was for earnings of $3.48 per share.
L

U.S. STOCKS Teck Resources, Nasdaq, T-Mobile

BUZZ-U.S. STOCKS ON THE MOVE-Teck Resources, Nasdaq, T-Mobile Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq rebounded on Thursday, after Tesla's upbeat earnings forecast lifted market sentiment following a selloff in the previous session, kicking off megacap results on a promising note.
A
B
D
H
N
T
T
L
L
T
T
U
U
D
S
T
C
L
R
T

Labcorp's quarterly results beat on diagnostic tests demand

UPDATE 1-Labcorp's quarterly results beat on diagnostic tests demand Adds analyst comment in paragraphs 5-6, changes story keyword used by media customers to LABCORP HLDG-RESULTS/ Oct 24 (Reuters) - Laboratory operator Labcorp LH.N beat Wall Street estimates for third-quarter profit and revenue on Thursday as strong demand for diagnostic tests offset a hit from hurricane-led disruptions.
L

Labcorp beats quarterly estimates on diagnostic test demand

Labcorp beats quarterly estimates on diagnostic test demand Oct 24 (Reuters) - Laboratory operator Labcorp LH.N on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests. Diagnostic checkups have risen in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic.
L

US lab operator Quest Diagnostics to launch bird flu test at end of October

US lab operator Quest Diagnostics to launch bird flu test at end of October Oct 23 - Lab operator Quest Diagnostics DGX.N said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus.
L

Labcorp Holdings Inc <LH.N> expected to post earnings of $3.49 a share - Earnings Preview

Labcorp Holdings Inc expected to post earnings of $3.49 a share - Earnings Preview Labcorp Holdings Inc LH.N , LH is expected to show a rise in quarterly revenue when it reports results on October 24 for the period ending September 30 2024 The Burlington North Carolina-based company is expected to report a 6.6% increase in revenue to $3.26 billion from $3.06 billion a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
L

NOWDiagnostics And Labcorp Collaborate To Expand Access To The Only Marketing Authorized Over-The-Counter Syphilis Test In The U.S.

BRIEF-NOWDiagnostics And Labcorp Collaborate To Expand Access To The Only FDA-Marketing Authorized Over-The-Counter Syphilis Test In The U.S. Oct 16 (Reuters) - Labcorp Holdings Inc LH.N : NOWDIAGNOSTICS AND LABCORP COLLABORATE TO EXPAND ACCESS TO THE ONLY FDA-MARKETING AUTHORIZED OVER-THE-COUNTER SYPHILIS TEST IN THE U.S. Source text for Eikon: ID
L

Labcorp Expands Sexually Transmitted Infection Test Offerings With Rapid Syphilis Test

BRIEF-Labcorp Expands Sexually Transmitted Infection Test Offerings With Rapid Syphilis Test Oct 10 (Reuters) - Labcorp Holdings Inc LH.N : LABCORP EXPANDS SEXUALLY TRANSMITTED INFECTION (STI) TEST OFFERINGS WITH RAPID SYPHILIS TEST LABCORP: PLANS TO MAKE TEST AVAILABLE TO PROVIDERS BY END OF 2024 AND DIRECTLY TO PATIENTS THROUGH LABCORP ONDEMAND I
L

WHO approves first mpox diagnostic test for emergency use

UPDATE 4-WHO approves first mpox diagnostic test for emergency use Updates Oct. 3 story to add company statement in paragraph 4 Oct 3 (Reuters) - The World Health Organization authorized Abbott Laboratories' ABT.N mpox diagnostic test for emergency use on Thursday, the first such approval in the agency's effort to bolster testing capabilities in countries facing outbreaks of the disease.
A
R
L

U.S. Amerant Bancorp, BlackRock, Equinix

U.S. RESEARCH ROUNDUP-Amerant Bancorp, BlackRock, Equinix Oct 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amerant Bancorp, BlackRock and Equinix, on Tuesday. HIGHLIGHTS * Amerant Bancorp Inc AMTB.N : Stephens raises to overweight from equal-weight * BlackRock BLK.N : JP Morgan raises target price to $864 from $774 * Equinix Inc EQIX.O : JP Morgan raises target price to $975 from $950 * Interpublic Group of Comp
A
P
C
L
R

U.S. STOCKS IonQ, Cassava Sciences, MeridianLink

BUZZ-U.S. STOCKS ON THE MOVE-IonQ, Cassava Sciences, MeridianLink Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
C
E
R
S
R
W
U
U
G
C
L

U.S. STOCKS Regeneron, HP Inc, Honeywell International

BUZZ-U.S. STOCKS ON THE MOVE-Regeneron, HP Inc, Honeywell International Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record high and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
A
C
E
L
R
S
W
W
U
U
D
C
L

Delay in reimbursement cut to ease pressure on U.S. lab operators, analysts say

BUZZ-Delay in reimbursement cut to ease pressure on U.S. lab operators, analysts say ** Delay in cuts to reimbursement rates for some lab tests under Medicare to aid 2025 rev and earnings of U.S. lab owners such as Labcorp LH.N and Quest Diagnostics DGX.N , analysts say ** LH shares rise 1.1% to $222.73, DGX shares up nearly 1% to $155.51 ** U.S. Congress on Wednesday deferred cuts to reimbursement rates from 2025 to 2026 ** "The delay was in-line with expectations as both LH and DGX have previo
L

U.S. Cardinal Health, Factset, Paylocity

U.S. RESEARCH ROUNDUP-Cardinal Health, Factset, Paylocity Sept 23 (Reuters) - .Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cardinal Health, Factset and Paylocity Holding on Monday. HIGHLIGHTS * Cardinal Health Inc CAH.N : Baird raises target price to $140 from $137 * Factset FDS.N : Jefferies raises target price to $486 from $435 * Marinus Pharmaceuticals Inc MRNS.O : Oppenheimer raises to outperform from perform * Paylocity
B
P
V
A
P
C
D
L
L
U

U.S. Factset, FedEx, Thermo Fisher Scientific

U.S. RESEARCH ROUNDUP-Factset, FedEx, Thermo Fisher Scientific Sept 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Factset, FedEx and Thermo Fisher Scientific on Friday. HIGHLIGHTS * Arthur J. Gallagher & Co. AJG.N : RBC raises target price to $320 from $310 * Factset FDS.N : RBC raises target price to $503 from $464 * FedEx Corp FDX.N : Baird cuts target price to $320 from $340 * IQVIA Holdings Inc IQV.N : Baird
A
A
A
B
D
E
N
X
T
A
D
I
L
P

Cinven To Sell Minority Stake In SYNLAB To Labcorp

BRIEF-Cinven To Sell Minority Stake In SYNLAB To Labcorp Sept 17 (Reuters) - Cinven: CINVEN: TO SELL MINORITY STAKE IN SYNLAB TO LABCORP CINVEN: PURCHASE PRICE FOR INDIRECT MINORITY STAKE OF 15% WAS ABOUT EUR 140 MILLION Further company coverage: LH.N
L

Labcorp Completes Acquisition Of Select Assets Of Bioreference Health's Diagnostics Business From Opko Health

BRIEF-Labcorp Completes Acquisition Of Select Assets Of Bioreference Health's Diagnostics Business From Opko Health Sept 16 (Reuters) - Labcorp Holdings Inc LH.N : LABCORP COMPLETES ACQUISITION OF SELECT ASSETS OF BIOREFERENCE HEALTH'S DIAGNOSTICS BUSINESS FROM OPKO HEALTH Source text for Eikon: ID:nPnbrzkBja Further company coverage: LH.N
O
L

U.S. Constellation Energy, Eli Lilly, Talen Energy

U.S. RESEARCH ROUNDUP-Constellation Energy, Eli Lilly, Talen Energy Sept 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Eli Lilly and Talen Energy, on Friday. HIGHLIGHTS * Constellation Energy Corp CEG.O : Jefferies initiates with hold rating; target $183 * Eli Lilly LLY.N : JP Morgan raises target price to $1,100 from $1,050 * Moderna MRNA.O : JP Morgan cuts to underweight from neutral * Vo
A
C
C
F
F
H
H
H
I
K
W
F
D
T
Z
A
A
D
E
H
L

Origin of human bird flu case in Missouri still unknown, U.S. CDC says

UPDATE 1-Origin of human bird flu case in Missouri still unknown, U.S. CDC says Adds context in paragraphs 7-12, bylines By Leah Douglas and Julie Steenhuysen WASHINGTON, Sept 12 (Reuters) - Epidemiologists have not yet identified exactly how a person in Missouri contracted bird flu last week, said the U.S. Centers for Disease Control and Prevention on Thursday.
L



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.